Track topics on Twitter Track topics that are important to you
The purpose of this research is to develop a new and powerful type of immune therapy for prostate cancer patients. This therapy involves vaccinations with special stimulator cells found in the human body called dendritic cells. These dendritic cells can take up proteins released from cancer cells and present pieces of these proteins to immune cells called T lymphocytes to create a strong stimulatory signal to fight the cancer.
One of these proteins is called telomerase, which is found on prostate cancers and is critically important for prostate cancer cells to grow. However, in most cancer patients, the immune system does not adequately destroy the tumor because the T cells are not stimulated sufficiently. T cells require strong stimulation before they grow and become active against cancer cells.
We have discovered that substances called ribonucleic acids (RNA), which carry the genetic instructions for the production of telomerase, can be used to overcome this problem and stimulate a strong immune response in cancer patients.
In order to test this hypothesis we have designed a clinical study and will enroll patients with metastatic prostate cancer expressing telomerase in order to determine whether or not this vaccine will stimulate T cells, which can recognize and kill prostate tumor cells.
The main objectives of this study are to find out whether injections with dendritic cells grown from blood cells and "pulsed" (mixed together for a short period of time) with RNA derived from the patient's own tumor are:
1. Safe without inducing any major side effects.
2. And effective in boosting the patient body's immunity against telomerase expressing prostate cancer cells.
3. Finally, we will test whether or not tumor shrinkage based on serum PSA levels or on X-ray studies will occur.
We hope that this new form of immune therapy, although in its infancy, will ultimately slow down tumor growth and prolong survival of prostate cancer patients.
Primary objectives of trial include to evaluate the safety and biologic efficacy of hTERT mRNA transfected dendritic cells (DC), applied in a prime-boost format, to stimulate hTERT-specific CD4+ and CD8+ T-cell responses in subjects with metastatic prostate cancer. Secondary objectives include estimating objective clinical response, the duration of such responses, progression-free survival and overall survival among all subjects. The hTERT mRNA-transfected DC vaccine platform has previously been studied in several phase I/II trials and has demonstrated safety and bioactivity in subjects with metastatic prostate and renal cell carcinomas. The objective of this trial is to enhance the observed bioactivity of the vaccine by using a prime-boost strategy. This is an open label, uncontrolled safety and efficacy study. Subjects with metastatic prostate cancer will be eligible for this study and will receive 1x107 cells administered ID at study week 1,2,3,4,5, and 6 (Prime). Thereafter, subjects will be randomized with equal probability to receive either 5x106 cells administered ID at study week 10 followed by monthly immunizations (Treatment arm A) or 1x107 cells administered ID at study week 10 followed by monthly immunizations (Treatment arm B). The safety, biologic and clinical efficacy of each regimen will be analyzed. The study will be solely conducted at the University of Florida in Gainesville, FL. Subjects will be recruited through the oncology clinics of the Departments of Urology and Radiation Oncology. The vaccine will be manufactured in a dedicated GMP-compliant cell production facility located on the 4th floor of the Cancer Genetics Research Institute. Immunological testing will be performed in the Immunological Monitoring Core laboratory of the Department of Urology using standardized assay systems. Subjects with histologically or clinically confirmed metastatic prostate cancer (stages pT1-4, N0-3, M+) are eligible for this study. Subjects treated with medical hormone ablative therapy (LHRH analogues or estrogens) should continue to receive LHRH analogues only. In subjects receiving nonsteroidal medical hormonal treatment (i.e. flutamide or bicalutamide) and who are experiencing a rising PSA, a 4 week period of observation will be required following the discontinuation of the nonsteroidal antiandrogen prior to study entry. Subjects will be excluded from study if they have received chemotherapy or other forms of immunotherapy in the 4 weeks prior to study entry. They must not have a history of autoimmune disease, serious intercurrent chronic or acute illness, pulmonary disease, active hepatitis, serologic evidence for HIV, or be receiving corticosteroid or immunosuppressive therapy. All subjects must be older than 18 years. This is a randomized phase II clinical trial, in which up to 36 subjects will be randomized with equal probability to one of the two treatment arms. The objective of this trial is to decide which of the two treatment regimens should be selected for further testing. Hence, the primary objective of this trial is to select the arm with the highest biologic response and the first ranked arm will be selected for further study in a larger efficacy trial.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Metastatic Prostate Cancer
hTERT mRNA DC, hTERT mRNA DC
Active, not recruiting
University of Florida
Published on BioPortfolio: 2014-08-27T03:12:35-0400
Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma
In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and surv...
The purpose of this study is to determine: 1. To evaluate the safety of activated T cell infusions and immunization with hTERT multi-peptide vaccine in the post-transplant setting ...
Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP is ...
vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma.
Telomerase and its core component, telomerase reverse transcriptase (hTERT), are critical for stem cell compartment integrity. Normal adult stem cells have the longest telomeres in a given tissue, a p...
Cancer cells, including head and neck cancer cell carcinoma (HNSCC), are characterized by an increased telomerase activity. This enzymatic complex is active in approximately 80-90% of all malignancies...
The present study aimed to examine associations of the testosterone/estradiol ratio, human leukocyte telomerase reverse transcriptase (hTERT) expression and telomerase activity of peripheral blood mon...
Bromodomain PHD finger transcription factor (BPTF), a core subunit of nucleosome-remodeling factor (NURF) complex, plays an important role in chromatin remodeling. However, its precise function and mo...
Telomerase activity can be detected in up to 90% of urothelial carcinomas (UC). Telomerase activity can also be detected in urinary tract cytology (UTC) specimens and indicate an increased risk of UC....
The addition of a tail of polyadenylic acid (POLY A) to the 3' end of mRNA (RNA, MESSENGER). Polyadenylation involves recognizing the processing site signal, (AAUAAA), and cleaving of the mRNA to create a 3' OH terminal end to which poly A polymerase (POLYNUCLEOTIDE ADENYLYLTRANSFERASE) adds 60-200 adenylate residues. The 3' end processing of some messenger RNAs, such as histone mRNA, is carried out by a different process that does not include the addition of poly A as described here.
An APOBEC deaminase catalytic subunit of the apolipoprotein B (APOB) MESSENGER RNA (mRNA) editing enzyme complex that is involved in post-transcriptional editing of a CAA codon for GLYCINE to a UAA STOP CODON in the ApoB mRNA. It also functions in CGA (ARGININE) to UGA STOP CODON editing of NEUROFIBROMIN 1 mRNA and EPIGENETIC PROCESSES.
An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A peptide initiation factor that binds specifically to the 5' MRNA CAP STRUCTURE of MRNA in the CYTOPLASM. It is a component of the trimeric complex EIF4F.
Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...